Form 4: TriSalus Life Sciences Director Wahlstrom Receives Stock Options

Mats Wahlstrom, a director of TriSalus Life Sciences, was granted stock options to purchase 15,000 shares of common stock on August 13, 2024.

Summary

• Mats Wahlstrom, a director of TriSalus Life Sciences, received a stock option grant on August 13, 2024.
• The options allow Wahlstrom to purchase 15,000 shares of TriSalus Life Sciences common stock at an exercise price of $5.75 per share.
• The options vest fully on the one-year anniversary of the grant date (August 13, 2025) or on the date of the Issuer's next annual stockholder meeting, whichever comes first, contingent upon Wahlstrom's continued service with the company.
• The options expire on August 12, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management interests with shareholders. There are no red flags or negative information presented.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the life sciences industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.

Key Dates